Adents and Microsoft pool resources to create new cloud platform

pharmafile | October 27, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Adents, EU, France, Microsoft 

Adents, a French software developer for unique production identification and ‘Track & Trace’ solutions, and Microsoft have developed, with an aim to commercialisation, a new cloud platform named Adents Prodigi. Adents Prodigi is the only Level 4 traceability solution that can centrally manage regulatory requirements upon the pharmaceutical industry. The platform also allows laboratories and CMOs to access the data generated during the serialisation and Track & Trace process.

The aim of the product is to improve upon unit identification and traceability; fight against the rise of counterfeit medicines, monitor productivity across production sites; enhance user experience and personalise communication whilst providing real-time data visualisation and analysis. The program relies on Microsoft Azure technologies and allows manufactures to securely generate, exchange and control the data that is create through unit identification.

“Our alliance with the leader of Business Intelligence will be a game changer on the global market for unit identification. Indeed, this will finally give the pharmaceutical industry the means to tap into the full potential of the wealth of information generated through serialization,” said Christophe Devins, founder and CEO of Adents.

“We are pleased qu’Adents chose the Microsoft AZURE platform to develop its solution and manage large masses of data generated during the life cycle of a product. Microsoft’s cloud platform will promote the secure deployment of the solution ADENTS internationally, which will accelerate the fight against industrial counterfeiting.” Commented Bernard Ourghanlian , technical and security director of Microsoft France, upon the announcement.

Ben Hargreaves

Related Content

Is the pharmaceutical sector prepared to face a titanium dioxide ban?

Dr Subhashis Chakraborty, head of Global Product Management, ACG Capsules In the wake of the …

EMA validates HUTCHMED MAA for neuroendocrine tumour drug

China-based biotech HUTCHMED has announced that the EMA has validated and accepted the Marketing Authorisation …

Visitors with non-EU approved jabs allowed in Madeira

Popular holiday destination, the Portuguese islands of Madeira, have announced that they will allow visitors …

Latest content